Total exploration time (s) | ||||
---|---|---|---|---|
Treatment group | Male | Female | Effect size | P value |
NOR | Â | Â | Â | Â |
 \(\text{ER}\alpha\)+/+sham+VC | 81 ± 7 | 75 ± 8 | 0.2 | 0.56 |
 \(\text{ER}\alpha\)+/+HI+VC | 78 ± 8 | 79 ± 6 | 0 | 0.91 |
 \(\text{ER}\alpha\)+/+HI+DHF | 91 ± 14 | 100 ± 10 | 0.2 | 0.62 |
 \(\text{ER}\alpha\)−/−sham+VC | 66 ± 13 | 60 ± 19 | 0.2 | 0.79 |
 \(\text{ER}\alpha\)−/−HI+VC | 88 ± 16 | 73 ± 21 | 0.3 | 0.63 |
\(\text{ER}\alpha\)−/−HI+DHF | 90 ± 10 | 85 ± 14 | 0.2 | 0.78 |
NOL | ||||
 \(\text{ER}\alpha\)+/+sham+VC | 70 ± 5 | 67 ± 5 | 0.2 | 0.64 |
 \(\text{ER}\alpha\)+/+HI+VC | 78 ± 6 | 58 ± 6 | 1 | 0.032 |
 \(\text{ER}\alpha\)+/+HI+DHF | 74 ± 15 | 80 ± 10 | 0.2 | 0.71 |
\(\text{ER}\alpha\)−/−sham+VC | 51 ± 9 | 51 ± 8 | 0 | 0.99 |
\(\text{ER}\alpha\)−/−HI+VC | 58 ± 5 | 92 ± 25 | 1.3 | 0.13 |
 \(\text{ER}\alpha\)−/−HI+DHF | 78 ± 13 | 65 ± 9 | 0.6 | 0.42 |